drugset / Trial / NCT02455726

Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease

NCT02455726

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Magnesium exerts analgesic effects in several animal pain models and in patients affected by acute postoperative pain and chronic pain of neuropathic origin. There is no evidence that magnesium can modulate pain in patients with peripheral arterial occlusive disease (PAOD). We describe the protocol of a single-center randomized double-blind clinical trial aimed at assessing the efficacy of oral magnesium supplementation in controlling severe pain in patients with advanced PAOD.

Timeline

Start
2015-09
Primary completion
2017-12
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified 5 mg
Background Pregabalin Small molecule 25 mg